First-in-Human Single Ascending Dose of SHR0302

Summary

The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) oral doses of SHR0302 compared to placebo. Also, pharmacokinetics (PK) and pharmacodynamics (PD) of SHR0302 after single oral administration will be evaluated, and, if applicable, the maximum tolerated dose determined.

Timeline

Start

2015-04

Primary completion

2016-07

Completion

—

Drugs

Indications